Literature DB >> 23918467

Motor development skills of 1- to 4-year-old Iranian children with early treated phenylketonuria.

Sepideh Nazi1, Farzaneh Rohani, Firoozeh Sajedi, Akbar Biglarian, Arya Setoodeh.   

Abstract

Objective : To gauge the gross and fine motor development of early treated phenylketonuria (ETPKU) in children in the age range of 1-4 years. Methods : A cross-sectional analytic study was conducted in PKU clinics (reference clinics for PKU follow-up), Tehran, Iran. Seventy children with ETPKU were selected as the case group for the study. ETPKU children were those with early and continuous treatment with a phenylalanine-restricted diet (the mean of blood phenylalanine level during the recent 6 months was 2-6 mg/dL or 120-360 μmol/L). Also, 100 healthy and normal children matched with the ETPKU group for age were randomly selected from 4 kindergartens in four parts of Tehran as a control group. The measurements consisted of a demographic questionnaire, Peabody Developmental Motor Scale-2 (PDMS-2), and pediatrician assessment. Motor quotients were determined by PDMS-2 and then compared in both groups by two independent samples t-test. Results : The mean ages in case and control group were 28.5 (± 11.6) and 29.7 (± 11.3) months, respectively. Comparison of the mean fine, gross, and total developmental motor quotients (DMQs) showed statistically significant differences between the two groups (p < 0.05). The fine and total DMQs of ETPKU children were also correlated with age. In addition, there was a negative correlation between the phenylalanine level and fine (p < 0.001) and total (p = 0.001) DMQs. Conclusion : It seems that ETPKU Iranian children, regardless of following a phenylalanine-restricted diet or not, have lower motor development. It is recommended to plan programs for early detection and intervention of developmental delays in these children.

Entities:  

Year:  2013        PMID: 23918467      PMCID: PMC3897793          DOI: 10.1007/8904_2013_248

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  18 in total

1.  Incidence of phenylketonuria in Iran estimated from consanguineous marriages.

Authors:  J Koochmeshgi; A Bagheri; S M Hosseini-Mazinani
Journal:  J Inherit Metab Dis       Date:  2002-02       Impact factor: 4.982

2.  Neurological outcome in 22 treated adolescents with hyperphenylalaninemia. A clinical and electrophysiological study.

Authors:  A C Ludolph; K Ullrich; S Nedjat; H Masur; U Bick
Journal:  Acta Neurol Scand       Date:  1992-04       Impact factor: 3.209

3.  Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population.

Authors:  Rosa Gassió; Rafael Artuch; Maria Antonia Vilaseca; Eugenia Fusté; Cristina Boix; Anna Sans; Jaume Campistol
Journal:  Dev Med Child Neurol       Date:  2005-07       Impact factor: 5.449

4.  Phenylketonuria in pediatric neurology practice: a series of 146 cases.

Authors:  Kalbiye Yalaz; Lale Vanli; Engin Yilmaz; Aysegul Tokatli; Banu Anlar
Journal:  J Child Neurol       Date:  2006-11       Impact factor: 1.987

Review 5.  Executive function in early-treated phenylketonuria: profile and underlying mechanisms.

Authors:  Shawn E Christ; Stephan C J Huijbregts; Leo M J de Sonneville; Desirée A White
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

Review 6.  Beyond executive function: non-executive cognitive abilities in individuals with PKU.

Authors:  Darren Janzen; Mina Nguyen
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

7.  Concurrent validity of the Bayley-III and the Peabody Developmental Motor Scale-2.

Authors:  Barbara H Connolly; Nancy Oberg McClune; Roberta Gatlin
Journal:  Pediatr Phys Ther       Date:  2012       Impact factor: 3.049

8.  Stability of blood phenylalanine levels and IQ in children with phenylketonuria.

Authors:  Vera Anastasoaie; Laura Kurzius; Peter Forbes; Susan Waisbren
Journal:  Mol Genet Metab       Date:  2008-08-13       Impact factor: 4.797

9.  Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis.

Authors:  Marieke Hoeksma; Dirk-Jan Reijngoud; Jan Pruim; Harold W de Valk; Anne M J Paans; Francjan J van Spronsen
Journal:  Mol Genet Metab       Date:  2009-02-06       Impact factor: 4.797

10.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

View more
  2 in total

1.  High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices.

Authors:  Orli Thau-Zuchman; Patrick N Pallier; Paul J M Savelkoul; Almar A M Kuipers; J Martin Verkuyl; Adina T Michael-Titus
Journal:  Front Neurosci       Date:  2022-09-29       Impact factor: 5.152

2.  Intellectual and Developmental Status in Children With Hyperphenylalaninemia and PKU Who Were Screened in a National Program.

Authors:  Parisa Aghasi; Arya Setoodeh; Azadeh Sayarifard; Maryam Rashidiyan; Fatemeh Sayarifard; Ali Rabbani; Javad Mahmoudi-Gharaei
Journal:  Iran J Pediatr       Date:  2015-12-23       Impact factor: 0.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.